MedPath
EMA Product

Duloxetine Lilly

Product approved by European Medicines Agency (EU)

Basic Information

Duloxetine Lilly

Regulatory Information

EMEA/H/C/004000

Authorised

December 8, 2014

October 23, 2014

10

July 9, 2024

Company Information

Netherlands

Papendorpseweg 83 3528 BJ Utrecht

Eli Lilly Nederland BV

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Duloxetine Lilly is indicated in adults for: - Treatment of major depressive disorder - Treatment of diabetic peripheral neuropathic pain - Treatment of generalised anxiety disorder Duloxetine Lilly is indicated in adults.

Overview Summary

This is a summary of the European public assessment report (EPAR) for Duloxetine Lilly. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Duloxetine Lilly. For practical information about using Duloxetine Lilly, patients should read the package leaflet or contact their doctor or pharmacist.

© Copyright 2025. All Rights Reserved by MedPath